EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients, treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the new Swedish (SE) EQ-5D preference sets, has not been previously described.

Detaljer

Författare
Enheter & grupper
Externa organisationer
  • Copenhagen University Hospital
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Reumatologi och inflammation
Originalspråkengelska
Artikelnummer51
TidskriftArthritis Research and Therapy
Volym18
Utgivningsnummer1
StatusPublished - 2016
PublikationskategoriForskning
Peer review utfördJa